Alkermes (NASDAQ:ALKS) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Alkermes (NASDAQ:ALKS) issued its quarterly earnings results on Wednesday. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.11, Zacks reports. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. Alkermes updated its FY 2025 guidance to 1.030-1.210 EPS.

Alkermes Trading Down 1.0 %

Shares of Alkermes stock traded down $0.35 on Friday, hitting $35.65. The stock had a trading volume of 526,375 shares, compared to its average volume of 1,660,176. The stock has a 50 day moving average of $30.31 and a 200 day moving average of $28.73. Alkermes has a twelve month low of $22.90 and a twelve month high of $36.25. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The firm has a market capitalization of $5.77 billion, a P/E ratio of 18.30, a PEG ratio of 1.83 and a beta of 0.49.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald decreased their target price on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Piper Sandler reissued an “overweight” rating and issued a $37.00 target price (down from $38.00) on shares of Alkermes in a research note on Friday, October 25th. Mizuho raised their target price on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and raised their price target for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. Finally, The Goldman Sachs Group raised their price target on Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Alkermes presently has an average rating of “Moderate Buy” and an average price target of $37.25.

Insider Activity

In other Alkermes news, SVP Christian Todd Nichols sold 5,208 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total transaction of $151,813.20. Following the completion of the sale, the senior vice president now owns 60,703 shares of the company’s stock, valued at approximately $1,769,492.45. This represents a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $31.85, for a total transaction of $85,708.35. Following the sale, the director now directly owns 23,013 shares of the company’s stock, valued at $732,964.05. This represents a 10.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 179,189 shares of company stock valued at $5,723,518 over the last quarter. 4.89% of the stock is owned by company insiders.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.